全文获取类型
收费全文 | 225篇 |
免费 | 17篇 |
国内免费 | 1篇 |
专业分类
儿科学 | 3篇 |
妇产科学 | 2篇 |
基础医学 | 30篇 |
口腔科学 | 4篇 |
临床医学 | 12篇 |
内科学 | 14篇 |
神经病学 | 22篇 |
特种医学 | 1篇 |
外科学 | 8篇 |
预防医学 | 2篇 |
药学 | 1篇 |
肿瘤学 | 144篇 |
出版年
2023年 | 2篇 |
2022年 | 1篇 |
2021年 | 6篇 |
2020年 | 4篇 |
2019年 | 3篇 |
2018年 | 1篇 |
2017年 | 3篇 |
2016年 | 2篇 |
2015年 | 11篇 |
2014年 | 26篇 |
2013年 | 10篇 |
2012年 | 17篇 |
2011年 | 17篇 |
2010年 | 11篇 |
2009年 | 4篇 |
2008年 | 13篇 |
2007年 | 14篇 |
2006年 | 18篇 |
2005年 | 16篇 |
2004年 | 13篇 |
2003年 | 10篇 |
2002年 | 7篇 |
2001年 | 10篇 |
2000年 | 4篇 |
1999年 | 1篇 |
1998年 | 6篇 |
1997年 | 4篇 |
1994年 | 1篇 |
1993年 | 1篇 |
1992年 | 1篇 |
1991年 | 3篇 |
1988年 | 1篇 |
1987年 | 1篇 |
1986年 | 1篇 |
排序方式: 共有243条查询结果,搜索用时 31 毫秒
1.
Conversion of myoblasts to physiologically active neuronal phenotype 总被引:13,自引:0,他引:13
Watanabe Y Kameoka S Gopalakrishnan V Aldape KD Pan ZZ Lang FF Majumder S 《Genes & development》2004,18(8):889-900
2.
Marsit CJ Wiencke JK Nelson HH Kim DH Hinds PW Aldape K Kelsey KT 《Cancer Genetics and Cytogenetics》2005,162(2):115-121
Tobacco smoke is well recognized as the major etiological contributor to lung cancer, yet the relationship between tobacco smoke exposure and a specific pattern of molecular abnormalities at somatic loci is less well characterized. We analyzed 100 primary tumors from patients undergoing surgical resection of squamous cell carcinoma and adenocarcinoma of the lung for loss of heterozygosity (LOH) and homozygous deletions at two microsatellite markers in a recombinogenic region of 9p13. We describe the relationship of alterations at these markers with tumor characteristics (both clinical and molecular), patient demographics, survival, and measures of tobacco-smoke exposure. Homozygous deletions in this region occurred in 25% (21/85) and LOH in 33% (28/85) of informative tumors examined. These alterations occurred more often in tumors with intense TP53 protein staining by immunohistochemistry, suggesting that inactivation of the TP53 pathway may contribute to these LOH events. Duration of smoking was greatest in patients with the homozygous deletion, intermediate in patients with LOH, and shortest in patients whose tumor did not demonstrate loss in these markers. Unexpectedly, LOH at 9p13 was a significant predictor of improved survival in patients, while the homozygous deletion was associated with the poorest patient survival. Together, these results suggest that TP53 alteration and long-term tobacco smoke exposure may contribute to genetic alterations at 9p13, and that the mechanism and biologic consequences of allele loss reflect individual biologic differences that determine the extent of loss (LOH or homozygous deletion), such that those patients with the deletion of this region face a more aggressive and deadly disease. 相似文献
3.
YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma. 总被引:7,自引:0,他引:7
Christopher E Pelloski Anita Mahajan Moshe Maor Eric L Chang Shiao Woo Mark Gilbert Howard Colman Helen Yang Alicia Ledoux Hilary Blair Sandra Passe Robert B Jenkins Kenneth D Aldape 《Clinical cancer research》2005,11(9):3326-3334
PURPOSE: YKL-40 is a secreted protein that has been reported to be overexpressed in epithelial cancers and gliomas, although its function is unknown. Previous data in a smaller sample set suggested that YKL-40 was a marker associated with a poorer clinical outcome and a genetically defined subgroup of glioblastoma. Here we test these findings in a larger series of patients with glioblastoma, and in particular, determine if tumor YKL-40 expression is associated with radiation response. EXPERIMENTAL DESIGN: Patients (n=147) with subtotal resections were studied for imaging-assessed changes in tumor size in serial studies following radiation therapy. An additional set (n=140) of glioblastoma patients who underwent a gross-total resection was tested to validate the survival association and extend them to patients with minimal residual disease. RESULTS: In the subtotal resection group, higher YKL-40 expression was significantly associated with poorer radiation response, shorter time to progression and shorter overall survival. The association of higher YKL-40 expression with poorer survival was validated in the gross-total resection group. In multivariate analysis with both groups combined (n = 287), YKL-40 was an independent predictor of survival after adjusting for patient age, performance status, and extent of resection. YKL-40 expression was also compared with genetically defined subsets of glioblastoma by assessing epidermal growth factor receptor amplification and loss at chromosome 10q, two of the common recurring aberrations in these tumors, using fluorescent in situ hybridization. YKL-40 was significantly associated with 10q loss. CONCLUSIONS: The findings implicate YKL-40 as an important marker of therapeutic response and genetic subtype in glioblastomas and suggest that it may play an oncogenic role in these tumors. 相似文献
4.
5.
Adriana Olar Khalida M. Wani Erik P. Sulman Alireza Mansouri Gelareh Zadeh Charmaine D. Wilson Franco DeMonte Gregory N. Fuller Kenneth D. Aldape 《Brain pathology (Zurich, Switzerland)》2015,25(3):266-275
While World Health Organization (WHO) grading of meningioma stratifies patients according to recurrence risk overall, there is substantial within‐grade heterogeneity with respect to recurrence‐free survival (RFS). Most meningiomas are graded according to mitotic counts per unit area on hematoxylin and eosin sections, a method potentially confounded by tumor cellularity, as well as potential limitations of accurate mitotic figure detection on routine histology. To refine mitotic figure assessment, we evaluated 363 meningiomas with phospho‐histone H3 (Ser10) and determined the mitotic index (number of mitoses per 1000 tumor cells). The median mitotic indices among WHO grade I (n = 268), grade II (n = 84) and grade III (n = 11) tumors were 1, 4 and 12. Classification and regression tree analysis to categorize cut‐offs identified three subgroups defined by mitotic indices of 0–2, 3–4 and ≥5, which on univariate analysis were associated with RFS (P < 0.01). In multivariate analysis, mitotic index subgrouped in this manner was significantly associated with RFS (P < 0.01) after adjustment for Simpson grade, WHO grade and MIB‐1 index. Mitotic index was then examined within individual WHO grade, showing that for grade I and grade II meningiomas, mitotic index can add additional information to RFS risk. The results suggest that the use of a robust mitotic marker in meningioma could refine risk stratification. 相似文献
6.
P R Connelly R A Aldape F J Bruzzese S P Chambers M J Fitzgibbon M A Fleming S Itoh D J Livingston M A Navia J A Thomson et al. 《Proceedings of the National Academy of Sciences of the United States of America》1994,91(5):1964-1968
Parallel measurements of the thermodynamics(free-energy, enthalpy, entropy and heat-capacity changes) of ligand binding toFK506 binding protein (FKBP-12) in H2O and D2O have been performed in an effortto probe the energetic contributions of single protein-ligand hydrogen bondsformed in the binding reactions. Changing tyrosine-82 to phenylalanine inFKBP-12 abolishes protein-ligand hydrogen bond interactions in the FKBP-12complexes with tacrolimus or rapamycin and leads to a large apparent enthalpicstabilization of binding in both H2O and D2O. High-resolution crystallographicanalysis reveals that two water molecules bound to the tyrosine-82 hydroxylgroup in unliganded FKBP-12 are displaced upon formation of the protein-ligandcomplexes. A thermodynamic analysis is presented that suggests that the removalof polar atoms from water contributes a highly unfavorable enthalpy change tothe formation of C=O...HO hydrogen bonds as they occur in the processes ofprotein folding and ligand binding. Despite the less favorable enthalpy change,the entropic advantage of displacing two water molecules upon binding leads to aslightly more favorable free-energy change of binding in the reactions withwild-type FKBP-12. 相似文献
7.
Farnaz C. Tahmasebi Peter Farmer Suzanne Z. Powell Kenneth D. Aldape Gregory N. Fuller Shital Patel Peter Hollis David Chalif Mark B. Eisenberg Jian Yi Li 《Virchows Archiv : an international journal of pathology》2013,462(4):473-480
Brain metastasis from papillary thyroid carcinoma (PTC) is extremely rare and carries a poor prognosis. We report nine cases (five females and four males) of brain metastasis of PTC. The age of patients ranged from 46 to 87 years old. The patients presented with nonspecific symptoms such as headaches. Brain metastasis was the first clinical presentation in three of nine patients; two of which had the aggressive tall cell variant of PTC. Six patients had prior history of PTC (four classic, one oncocytic variant, and one columnar cell variant) for 2 to 17 years with a median of 12 years. Gross total resection of brain metastasis was achieved for eight of our patients. Eight patients were treated with radioactive iodine. The median follow-up time was 12 months, ranging from 1 month to 4 years. Three patients died of their disease in 6 months, 21 months and 4 years, respectively after their first presentation of brain metastasis. It seems that these rare aggressive variants of PTC, such as tall cell variant, not only have higher propensity to develop brain metastasis, but also more frequently present with brain metastasis as their first clinical presentation than classic PTC. Furthermore, patients with PTC can develop brain metastasis even after many years. 相似文献
8.
David W. Ellison Kenneth D. Aldape David Capper Maryam Fouladi Mark R. Gilbert Richard J. Gilbertson Cynthia Hawkins Thomas E. Merchant Kristian Pajtler Sriram Venneti David N. Louis 《Brain pathology (Zurich, Switzerland)》2020,30(5):863-866
Advances in our understanding of the biological basis and molecular characteristics of ependymal tumors since the latest iteration of the World Health Organization (WHO) classification of CNS tumors (2016) have prompted the cIMPACT‐NOW group to recommend a new classification. Separation of ependymal tumors by anatomic site is an important principle of the new classification and was prompted by methylome profiling data to indicate that molecular groups of ependymal tumors in the posterior fossa and supratentorial and spinal compartments are distinct. Common recurrent genetic or epigenetic alterations found in tumors belonging to the main molecular groups have been used to define tumor types at intracranial sites; C11orf95 and YAP1 fusion genes for supratentorial tumors and two types of posterior fossa ependymoma defined by methylation group, PFA and PFB. A recently described type of aggressive spinal ependymoma with MYCN amplification has also been included. Myxopapillary ependymoma and subependymoma have been retained as histopathologically defined tumor types, but the classification has dropped the distinction between classic and anaplastic ependymoma. While the cIMPACT‐NOW group considered that data to inform assignment of grade to molecularly defined ependymomas are insufficiently mature, it recommends assigning WHO grade 2 to myxopapillary ependymoma and allows grade 2 or grade 3 to be assigned to ependymomas not defined by molecular status. 相似文献
9.
Kohei Fukuoka Yasin Mamatjan Scott Ryall Martin Komosa Julie Bennett Michal Zapotocky Julia Keith Sten Myrehaug Lili‐Naz Hazrati Kenneth Aldape Norm Laperriere Eric Bouffet Uri Tabori Cynthia Hawkins 《Brain pathology (Zurich, Switzerland)》2020,30(3):515-523
We performed genome‐wide methylation analysis on 136 pediatric low‐grade gliomas, identifying a unique cluster consisting of three tumors with oligodendroglioma‐like histology, BRAF p.V600E mutations and recurrent whole chromosome gains of 7 and loss of 10. Morphologically, all showed similar features, including a diffusely infiltrative glioma composed of round nuclei with perinuclear halos, a chicken‐wire pattern of branching capillaries and microcalcification. None showed astrocytic features or characteristics suggestive of high‐grade tumors including necrosis or mitotic figures. All tumors harbored multiple chromosomal copy number abnormalities (>10 chromosomes altered), but none showed 1p/19q co‐deletion or IDH1 p.R132H mutation. Hierarchical clustering and t‐stochastic neighbor embedding analyses from DNA methylation data cluster them more closely to previously described pediatric‐type low‐grade gliomas and separate from adult gliomas. These tumors exhibit distinct clinical features; they are temporal lobe lesions occurring in adolescents and young adults with a prolonged history of seizures and all are alive with no recurrence (follow‐up 3.2 to 13.2 years). We encountered another young adult case with quite similar pathological appearance and molecular status except for TERT promoter mutation. Although the series is small, these may represent a new category of IDH wild‐type low‐grade gliomas which may be confused with “molecular GBM.” Further, they highlight the heterogeneity of IDH wild‐type gliomas and the relatively indolent behavior of “pediatric‐type” gliomas. 相似文献
10.
Joseph Driver Samantha E Hoffman Sherwin Tavakol Eleanor Woodward Eduardo A Maury Varun Bhave Noah F Greenwald Farshad Nassiri Kenneth Aldape Gelareh Zadeh Abrar Choudhury Harish N Vasudevan Stephen T Magill David R Raleigh Malak Abedalthagafi Ayal A Aizer Brian M Alexander Keith L Ligon David A Reardon Patrick Y Wen Ossama Al-Mefty Azra H Ligon Adrian M Dubuc Rameen Beroukhim Elizabeth B Claus Ian F Dunn Sandro Santagata Wenya Linda Bi 《Neuro-oncology》2022,24(5):796
BackgroundMeningiomas are the most common primary intracranial tumor in adults. Clinical care is currently guided by the World Health Organization (WHO) grade assigned to meningiomas, a 3-tiered grading system based on histopathology features, as well as extent of surgical resection. Clinical behavior, however, often fails to conform to the WHO grade. Additional prognostic information is needed to optimize patient management.MethodsWe evaluated whether chromosomal copy-number data improved prediction of time-to-recurrence for patients with meningioma who were treated with surgery, relative to the WHO schema. The models were developed using Cox proportional hazards, random survival forest, and gradient boosting in a discovery cohort of 527 meningioma patients and validated in 2 independent cohorts of 172 meningioma patients characterized by orthogonal genomic platforms.ResultsWe developed a 3-tiered grading scheme (Integrated Grades 1-3), which incorporated mitotic count and loss of chromosome 1p, 3p, 4, 6, 10, 14q, 18, 19, or CDKN2A. 32% of meningiomas reclassified to either a lower-risk or higher-risk Integrated Grade compared to their assigned WHO grade. The Integrated Grade more accurately identified meningioma patients at risk for recurrence, relative to the WHO grade, as determined by time-dependent area under the curve, average precision, and the Brier score.ConclusionWe propose a molecularly integrated grading scheme for meningiomas that significantly improves upon the current WHO grading system in prediction of progression-free survival. This framework can be broadly adopted by clinicians with relative ease using widely available genomic technologies and presents an advance in the care of meningioma patients. 相似文献